Liquid biopsies offer minimally invasive diagnosis and monitoring of cancer disease. This biosource is often analyzed using sequencing, which generates highly complex data that can be used using machine learning tools. Nevertheless, validating the clinical applications of such methods is challenging. It requires: (a) using data from many patients; (b) verifying potential bias concerning sample collection; and (c) adding interpretability...

Liquid biopsy is a useful, minimally invasive diagnostic and monitoring tool for cancer disease. Yet, developing accurate methods, given the potentially large number of input features, and usually small datasets size remains very challenging. Recently, a novel feature parameterization based on the RNA-sequenced platelet data which uses the biological knowledge from the Kyoto Encyclopedia of Genes and Genomes, combined with a classifier...